Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.65 |
| ▸ | CTSK | P43235 | 1/20 | 0.65 |
| ▸ | PAM | P19021 | 1/20 | 0.65 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.60 |
| ▸ | TACR1 | P25103 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GNPAT | O15228 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13255164 | 1.00 | CTSS (0.65) | CTSSCTSKPAMCTRB1TACR1 | |
| SCHEMBL5745614 | 1.00 | CTSS (0.65) | CTSSCTSKPAMCTRB1TACR1 | |
| SCHEMBL6248471 | 0.89 | CTSS (0.61) | CTSSCTSKPAMCTRB1TACR1 | |
| SCHEMBL15810860 | 0.89 | CTSS (0.61) | CTSSCTSKPAMCTRB1TACR1 | |
| SCHEMBL15810862 | 0.89 | CTSS (0.61) | CTSSCTSKPAMCTRB1TACR1 | |
| SCHEMBL4028404 | 0.89 | ALDH1A1 (0.57) | CTSSCTSKPAMCTRB1TACR1 | |
| Afalanine SCHEMBL8587729 | 0.89 | CTSS (0.65) | CTSSCTSKPAMCTRB1TACR1 | |
| Afalanine SCHEMBL158612 | 0.89 | CTSS (0.65) | CTSSCTSKPAMCTRB1TACR1 | |
| Afalanine SCHEMBL158613 | 0.89 | CTSS (0.65) | CTSSCTSKPAMCTRB1TACR1 | |
| Afalanine SCHEMBL331330 | 0.89 | CTSS (0.65) | CTSSCTSKPAMCTRB1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234553-A2 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021113743-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2020223209-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | Aerpio Pharmaceuticals, Inc. (US) | 2020-11-05 | — | — | WO | disclosed |
| EP-3607821-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Therapeutics, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20170319602-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint, Inc. | 2017-11-09 | — | — | US | disclosed |
| US-9440963-B2 | Compositions, formulations and methods for treating ocular diseases | AERPIO THERAPEUTICS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160220540-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160220541-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-9376700-B2 | Methods of modifying N-termini of a peptide or protein using transferases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-06-28 | — | — | US | disclosed |
| WO-2011150457-A2 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-12-08 | — | — | WO | disclosed |
| US-20110130349-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| US-7838548-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-23 | — | — | US | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-7550501-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20090018343-A1 | Fluorous Oxazolidinone Chiral Auxiliary Compounds and Methods of Manufacture | THE UNIVERSITY OF MANITOBA (CA) | 2009-01-15 | — | — | US | disclosed |
| WO-2008022365-A2 | COMPOSITIONS FOR INFLUENCING THE EFFECTS OF ORGANOPHOSPHORUS COMPOUNDS AND USE OF GALANTHAMINE, ITS DERIVATIVES AND ANALOGUES FOR PRODUCING SUCH COMPOSITIONS | SANOCHEMIA LTD. (MT) | 2008-02-28 | — | — | WO | disclosed |
| US-7202234-B2 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | EISAI CO., LTD. (JP) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220541-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | CTSS 3152/4885CTSK 2130/4885PAM 4556/4885 |
| US-20170319602-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | CTSS 1339/4885CTSK 630/4885PAM 4233/4885 |
| US-20090018343-A1 | Fluorous Oxazolidinone Chiral Auxiliary Compounds and Methods of Manufacture | AFF2, FPR2, PFAS | CTSS 3306/4885CTSK 3263/4885PAM 2173/4885 |
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | TLR2, TLR6, TLR3 | CTSS 1951/4885CTSK 1659/4885PAM 2408/4885 |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | CTSS 875/4885CTSK 1368/4885PAM 4270/4885 |
| US-20160220540-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | CTSS 3152/4885CTSK 2130/4885PAM 4556/4885 |
| US-20110130349-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | TLR2, TLR6, TLR3 | CTSS 1951/4885CTSK 1659/4885PAM 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.